Evidence mapPaperPMID 41501875Full record

ArticleGlobalization and health2026

Country governance of antimicrobial resistance (AMR) surveillance: observations on global progress and aid programme effectiveness using data from the Tracking AMR Country Self-Assessment Survey (TrACSS).

Archie Drake, Isabel Sassoon, Jennifer Armitage, Syed Abbas, Rebecca Maudling, Ankur Gupta-Wright, Alan Serrano, Anila Shafa, Tim Shorten

Abstract read
In one paragraph

Article in Globalization and health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Archie DrakeIndependent Consultant, Dar es Salaam, United Republic of Tanzania. archiedrake@outlook.com.
Isabel SassoonBrunel University of London, London, UK.
Jennifer ArmitageLAMP Development Organisation Ltd, Edinburgh, UK.
Syed AbbasInstitute of Development Studies, Brighton, UK.
Rebecca MaudlingIndependent Consultant, London, UK.
Ankur Gupta-WrightImperial College London, London, UK.
Alan SerranoBrunel University of London, London, UK.
Anila ShafaItad Ltd, Brighton, UK.
Tim ShortenIndependent Consultant, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAMR is an important global public health challenge, but there is a lack of good data on response progress. This study addresses country governance of antimicrobial resistance (AMR) surveillance, considering changes in responses to the Tracking Antimicrobial Resistance Country Self-Assessment Survey (TrACSS) between 2019 and 2024. Its first objective is to describe progress under the global action agenda on AMR. Its second objective is to assess the effectiveness of a major development aid intervention to encourage action against AMR, the United Kingdom (UK)-funded Fleming Fund (FF). The study applies a pragmatic approach to analysis, involving descriptive exploration and difference-in-differences methodology.

resultsGovernance of AMR surveillance in low- and middle-income countries generally strengthened over the five years to 2024, converging with high-income countries (HIC). South-East Asian countries reported relatively strong gains, a striking exception to limited global progress. Globally, over fifteen indicators, clear progress was only reported in four: two on strengthening underlying AMR surveillance systems, in both human health (HH) and animal health (AH); and two on regulatory frameworks in AH. FF-supported countries reported strengthening HH surveillance systems more than comparable countries, even accounting for income-group differences. The standardised change score for the 'national surveillance system for AMR in humans' was 0.11 higher in FF-supported than in other Official Development Assistance (ODA)-eligible countries (95% confidence level, p = 0.046). FF-supported countries also reported greater progress on other topics, such as use of surveillance data for decision-making in AH. FF-supported countries were approximately a quarter (25%) more likely to respond 'yes' on this topic. Additional reflections on the strengths and weaknesses of TrACSS data are discussed in detail.

conclusionOur study adds empirical observations about country governance systems as they relate to AMR surveillance efforts. The idea of progressive global momentum, with South-East Asia playing a key role, disrupts established perceptions of European leadership and obstacles to change. From an aid effectiveness perspective, this study indicates that FF strengthened country HH and AH surveillance systems. It also points to institutional changes in how data are used in administrative decision-making processes and, potentially, in the translation of evidence into policy, programmes and regulation. CLINICAL TRIAL NUMBER: Not applicable.

Indexed as

Drug Resistance, MicrobialGlobal HealthInternational CooperationPopulation SurveillanceDeveloping CountriesHumansProgram EvaluationSurveys and QuestionnairesAntimicrobial resistance (AMR)Development effectivenessEvaluationGovernanceOne healthPolicyPublic health surveillanceRegulationTrACSS

Identifiers

PMID41501875
PMCPMC12822036

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.